The OUtMATCH Study

Now Enrolling: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH)

The OUtMATCH Study Banner Photo

Study Objectives & Details: Our researchers are trying to determine if a study medication called omalizumab alone or combined with oral immunotherapy may help people with multiple food allergies. Participants must have a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut, or walnut.

Enrollment: This trial is active and currently enrolling.

How to Participate: For more information, call (404) 785-6448 to speak with a coordinator or email

Who Can Participate: Anyone between the ages of 1-55 years who has a peanut allergy and at least two other food allergies to milk, egg, wheat, cashew, hazelnut or walnut.

  • Age Range: 1-55 years
  • Gender: Any

Estimated Time Commitment (# of visits, etc.): This is a multi-stage study, with individual study participation of up to 4 years and 8 months, but not past December 2023. 

Study Location: Children’s Healthcare of Atlanta - Center for Advanced Pediatrics

Compensation: Provided

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Site Principal Investigator: Brian Vickery, MD
Study Coordinators: Ashley Dulson, Mary Vess and Randi Sylve
Study Primary Investigator: Robert Wood, MD
Co-Investigator(s): Meera Patrawala, MD and Tricia Lee, MD

Contact us: There are several ways to learn more about the study. You may reach us via one of the options below.


For additional information about our research program and the currently available clinical trials, visit our website here:  Food Allergy Center @ Emory+Children's

Feel free to use the form below to contact us